Updated trial data: Recent social media chatter centers on Corbus Pharmaceuticals' release of fresh Phase 1/2 results for its CRB-701 antibody-drug conjugate in second-line oropharyngeal and cervical cancers, highlighting response rates tied to HPV status ahead of the ASCO meeting.
Market reaction: Observers note the data's robustness and the company's plans to launch a registrational trial this summer, even as shares retreated sharply following the announcement, prompting some participants to add to positions on the pullback.
Future catalysts: Discussion also flags upcoming obesity-related readouts later in the year as potential drivers, with traders expressing interest in how the cancer program positions the firm for broader pipeline advancement.
Note: This discussion summary was generated from an AI condensation of post data.
Corbus Pharmaceuticals Insider Trading Activity
Corbus Pharmaceuticals insiders have traded $CRBP stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CRBP stock by insiders over the last 6 months:
- DOMINIC SMETHURST (Chief Medical Officer) sold 3,285 shares for an estimated $26,574
- IAN HODGSON (Chief Operating Officer) sold 2,415 shares for an estimated $19,537
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Corbus Pharmaceuticals Hedge Fund Activity
We have seen 55 institutional investors add shares of Corbus Pharmaceuticals stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP removed 955,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,967,450
- VANGUARD GROUP INC added 247,377 shares (+40.4%) to their portfolio in Q4 2025, for an estimated $2,013,648
- ARMISTICE CAPITAL, LLC removed 172,000 shares (-32.1%) from their portfolio in Q1 2026, for an estimated $1,615,080
- ORBIMED ADVISORS LLC added 140,000 shares (+8.8%) to their portfolio in Q1 2026, for an estimated $1,314,600
- AMERIPRISE FINANCIAL INC removed 135,730 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,274,504
- TANG CAPITAL MANAGEMENT LLC removed 127,520 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,038,012
- HIGHVISTA STRATEGIES LLC removed 118,027 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $960,739
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Corbus Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $CRBP recently. We have seen 4 analysts offer price targets for $CRBP in the last 6 months, with a median target of $44.5.
Here are some recent targets:
- Graig Suvannavejh from Mizuho set a target price of $44.0 on 05/22/2026
- Paul Jeng from Guggenheim set a target price of $45.0 on 05/13/2026
- Jeff Jones from Oppenheimer set a target price of $54.0 on 05/13/2026
- Maury Raycroft from Jefferies set a target price of $33.0 on 05/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
